{"a":[{"_":"Novartis claims MS win as Rhapsido clears phase 3 with ‘no liver safety signal’","$":{"href":"/pharma/novartis-claims-ms-win-rhapsido-remibrutinib-clears-phase-3-no-liver-safety-signal","hreflang":"en"}}]}
Phase 3positiveRhapsidoPositive
AI Analysis
Summary
Novartis announced positive Phase 3 trial results for Rhapsido (remibrutinib) in relapsing multiple sclerosis, with both trials meeting their endpoints and no liver safety concerns observed. The BTK inhibitor class has faced safety challenges, making this a notable advancement.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Two phase 3 trials met their primary goals with no liver safety signals
Importance:8/10
Sentiment:
0.85
Phase 3 dataMSBTK inhibitorSafety profileMultiple sclerosis
Related Companies
Read the original article
Published by FiercePharma on September 1, 2026 10:17 AM